Effects of CIK Immunotherapy Combined with Nedaplatin+Paclitaxel Chemotherapy on Quality of Life in Esophageal Cancer
WANG Mengdie
QI Ningning
HOU Yuan
Abstract：Objective To observe the influences of cytokine induced killer(CIK)immunotherapy combined with nedaplatin+paclitaxel chemotherapy on clinical curative effect and quality of life in patients with esophageal cancer.Methods 66 patients with esophageal cancer admitted to our hospital were selected from January 2020 to January 2022,and were randomly divided into study group(n=33)and control group(n=33).The control group was given nedaplatin+paclitaxel chemotherapy,while the study group was additionally given CIK immunotherapy.The clinical curative effect,immune indexes,quality of life and toxicity before and after treatment,and survival within 24 months of follow-up in the two groups were compared.Results The objective response rate(ORR)and disease control rate(DCR)in study group were higher than those in control group(P<0.05).After treatment,levels of serum T lymphocyte subsets CD3+,CD4+,CD4+/CD8+in study group were higher than those in control group(P<0.05).The score of Karnofsky performance status(KPS)in study group was higher than that in control group(P<0.05).During treatment,total incidence of toxicity(myelosuppression,liver-kidney function impairment)in study group was lower than that in control group(P<0.05).The follow-up results showed that 12-month and 24-month survival rates in study group were higher than those in control group(P<0.05).Conclusion CIK immunotherapy combined with nedaplatin+paclitaxel chemotherapy can effectively improve clinical curative effect,immune function and quality of life in patients with esophageal cancer,reduce toxicity and prolong survival time to certain extent.
Keywords：cytokine induced killercellular immunitynedaplatinpaclitaxelesophageal cancerquality of life
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 87-91 )